The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II study of neoadjuvant, intra-arterial administration of (177Lu)lutetium vipivotide tetraxetan in subjects with high-risk, localised or locally advanced prostate cancer (LUPUS).
 
Claudia Kesch
Speakers' Bureau - Novartis; Pfizer
Research Funding - Amgen; Mariana Oncology; Novartis
Patents, Royalties, Other Intellectual Property - Mucoadhesive Polymeric Drug Delivery Compositions and Methods; Polymeric Paste Compositions for Drug Delivery
Travel, Accommodations, Expenses - Bayer
 
Volker Meyer
No Relationships to Disclose
 
Christine Praus
Consulting or Advisory Role - Janssen-Cilag
 
Pedro Fragoso Costa
No Relationships to Disclose
 
Marc Ingenwerth
No Relationships to Disclose
 
Christopher Darr
Stock and Other Ownership Interests - Bayer
Honoraria - Bayer; Ipsen; Janssen; MSD
Consulting or Advisory Role - Bayer; Ipsen; Janssen
Research Funding - Deutsche Forschungsgemeinschaft (Inst)
Travel, Accommodations, Expenses - Bayer; Ipsen; Janssen; Xeos medical
 
Jan Radtke
Stock and Other Ownership Interests - Intuitive.
Honoraria - Beckelmann und Partner; Dr. Wolff Group
Consulting or Advisory Role - Astellas Pharma; AstraZeneca
Research Funding - Novartis
Expert Testimony - Johnson & Johnson; Novartis; Siegelring Medizintechnik
Travel, Accommodations, Expenses - Bayer Healthineers; Johnson & Johnson; Novartis
 
Jens Theysohn
No Relationships to Disclose
 
Benedikt Schaarschmidt
Speakers' Bureau - AstraZeneca
Research Funding - Pharmazeut AG
Travel, Accommodations, Expenses - Bayer
 
Henning Reis
Honoraria - Astellas Pharma; AstraZeneca; Boehring-Ingelheim; Bristol-Myers Squibb; CHOP GmbH; Diaceutics; Evidia; GlaxoSmithKline; HUeG e. V.; Janssen-Cliag; Menarini Group; Merck; Miami Cancer Institute; Novartis; Roche; Sanofi; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; CHOP GmbH; Diaceutics; Evidia; GlaxoSmithKline; HUeG e.V.; Janssen-Cliag; Menarini Group; Merck; Miami Cancer Institute; Novartis; Roche; Sanofi; Takeda
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Philips Healthcare; Roche
 
Wolfgang Fendler
Honoraria - Parexel
Consulting or Advisory Role - Calyx; GE Healthcare; Janssen; Lilly
Speakers' Bureau - ABX Advanced biochemical compounds; Amgen; Bayer; Eczacibasi Monrol; GE Healthcare; Janssen; Novartis; Telix Pharmaceuticals
Research Funding - SOFIE
 
Viktor Grünwald
Employment - University Hospital Essen
Stock and Other Ownership Interests - AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Genmab; MSD
Honoraria - Advanced Accelerator Applications/Novartis; Amgen; Apogepha; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Ipsen; Janssen-Cilag; Merck Serono; MSD Oncology; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Cureteq; Debiopharm Group; Eisai; Gilead Sciences; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Oncorena; PCI Biotech; Pfizer; Synthekine
Research Funding - Amgen (Inst); Bicycle Therapeutics (Inst); BMS (Inst); Gilead Sciences (Inst); Ipsen (Inst); MSD Oncology (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Janssen; Merck Serono; Pfizer
 
Boris Hadaschik
Consulting or Advisory Role - ABX Advanced biochemical compounds; Accord Healthcare; Amgen; Astellas Pharma; Bayer; BMS GmbH & Co. KG; Ipsen; Janssen; Lightpoint medical; Merck KGaA; MSD; Novartis; Onkowissen; Pfizer; POINT Biopharma
Research Funding - Bristol Myers Squibb (Inst); Janssen; Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Uromed
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; BMS; Ipsen; Janssen
(OPTIONAL) Uncompensated Relationships - German Association of Urology
 
Ken Herrmann
Leadership - Aktis Oncology; Pharma15
Stock and Other Ownership Interests - AdvanCell; Aktis Oncology; Convergent Therapeutics; SOFIE
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; AstraZeneca; Bain Capital; Bayer; Boston Scientific; BTG; Debiopharm Group; Fusion Pharmaceuticals; GE Healthcare; Immedica; IPSEN; ITG (Inst); Janssen Oncology; Molecular Partners; Novartis; Radiopharm Theranostics; ROTOP Pharmaka (Inst); Siemens Healthineers; Telix Pharmaceuticals